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Abstract
Background: Demyelinating polyneuropathy is a debilitating, poorly understood disease that can exist in acute (Guillain-
Barre ´ syndrome) or chronic forms. Interleukin-10 (IL-10), although traditionally considered an anti-inflammatory cytokine,
has also been implicated in promoting abnormal angiogenesis in the eye and in the pathobiology of autoimmune diseases
such as lupus and encephalomyelitis.
Principal Findings: Overexpression of IL-10 in a transgenic mouse model leads to macrophage-mediated demyelinating
polyneuropathy. IL-10 upregulates ICAM-1 within neural tissues, promoting massive macrophage influx, inflammation-
induced demyelination, and subsequent loss of neural tissue resulting in muscle weakness and paralysis. The primary insult
is to perineural myelin followed by secondary axonal loss. Infiltrating macrophages within the peripheral nerves
demonstrate a highly pro-inflammatory signature. Macrophages are central players in the pathophysiology, as in vivo
depletion of macrophages using clodronate liposomes reverses the phenotype, including progressive nerve loss and
paralysis. Macrophage-mediate demyelination is dependent on Fas-ligand (FasL)-mediated Schwann cell death.
Significance: These findings mimic the human disease chronic idiopathic demyelinating polyneuropathy (CIDP) and may
also promote further understanding of the pathobiology of related conditions such as acute idiopathic demyelinating
polyneuropathy (AIDP) or Guillain-Barre ´ syndrome.
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Introduction
Macrophages carry out a wide variety of biological functions
and their ultimate effector phenotype is largely dependent upon
activation and polarization. Polarization, in turn, is regulated by
the dominant cytokine signature in the resident tissue microenvi-
ronment [1,2]. Macrophages can acquire a ‘‘classically-activated’’
phenotype (i.e. M1 macrophage) and display an anti-angiogenic,
anti-bacterial, and pro-inflammatory functions; or an ‘‘alterna-
tively-activated’’ phenotype (i.e. M2 macrophages) and display a
pro-angiogenic and anti-inflammatory phenotype. Of the cyto-
kines involved in macrophage polarization, the immunosuppres-
sive cytokine interleukin 10 (IL-10) plays a highly robust role in
M2 polarization. IL-10-mediated polarization of macrophages
towards an M2 phenotype has a detrimental affect on the ability of
macrophages to regulate abnormal angiogenesis as seen in the eye
[1,3,4]. This has particular relevance to the eye as age-related
macular degeneration (AMD), the leading cause of blindness in
people over 50 years of age, is characterized by the development of
abnormal blood vessels underneath the retina called choroidal
neovascularization (CNV). In mouse models of CNV in AMD, IL-
10 promotes pathological neovascularization by preventing
macrophage infiltration into the choroid and by polarizing
macrophages to a pro-angiogenic M2 phenotype [3]. IL-10 has
also been shown to promote pathological angiogenesis in the retina
following ischemia [4].
Our laboratory was interested in exploiting the pro-angiogenic
and anti-inflammatory properties of IL-10 in a model of age-
related macular degeneration (AMD). We constructed transgenic
mice expressing murine IL-10 under the control of the human
VMD2 gene promoter in B6CBAF2/J founder mice [3]. VMD2 is
located on chromosome 11q13, and encodes the 585 aa protein
Bestrophin. Mutations in VMD2 have been implicated in Best
vitelliform macular dystrophy and AMD, and bestrophin was
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membrane of retinal pigment epithelium (RPE) cells [5]. VMD2-
IL10 transgenic mice expressed high levels of secreted IL-10 in the
retina, and were prone to develop CNV following laser-injury [3].
After creation of VMD2-IL-10 transgenic mice, our laboratory
began to backcross these mice to a C57BL/6 background.
Surprisingly, IL-10 transgene-positive mice at the F5 backcross
generation developed spontaneous hindlimb weakness around 3-
months of age, followed by eventual paralysis. Veterinary necropsy
of diseased animals revealed swollen peripheral nerves, with
necrotic lesions and immune cell infiltrate. This pattern of
paralysis continued through subsequent generations of transgenic
mice. At the F11 backcross generation, transgenic mice were
monitored for development of paralysis twice weekly, using a
modified grading scale similar to mouse EAE models [6]. In this
study we explore the pathobiology of the autoimmune polyneu-
ropathy associated with transgenic IL-10 overexpression.
Results
Mice positive for the IL-10 transgene as determined by PCR
analysis developed hind limb paralysis (Fig. 1A). Paralysis was
restricted to hind limbs of transgene positive (Tg+) mice, as
paralysis of the tail was not observed. Transgene negative (Tg2)
littermates did not develop hind limb paralysis (Fig. 1A). Disease
onset varied from 2-4 months of age, and Tg+ mice ,2 months of
age showed no overt loss of motor function.
As stated above, VMD2 was originally identified as being
localized to RPE cells. However, subsequent data has shown that
human VMD2 is expressed in multiple sites within the human
body [7]. GeneAtlas analysis reveals that in humans, VMD2 is
highly expressed in the nervous system, including the spinal cord
and multiple areas of the brain. For mice, murine VMD2 appears
to be primarily expressed in the eye and testes [8]. However, the
full expression pattern of human VMD2 within murine tissues is
unknown. Since human VMD2 was driving murine IL-10
expression in the Tg+ mice, we examined gene expression of
murine IL-10 in multiple tissues from Tg+ sick mice compared to
normal Tg2 control littermates, as Tg2 tissues should express
baseline levels of IL-10. We found increased expression of IL-10 in
the eye, sciatic nerve, spinal cord, testes, and brain of Tg+ sick
mice relative to IL-10 levels in the same tissues from Tg2 mice
(Fig. 2A). Similar expression patterns of IL-10 were observed in
Tg+ healthy mice relative to Tg2 mice (data not shown). Based on
studies demonstrating high VMD2 expression in the testes, and
since IL-10 gene expression was 55,000 fold higher in the testes of
Tg+ mice, we sought to determine if increased IL-10 gene
expression in the testes of male Tg+ mice may exacerbate
development of disease compared to female Tg+ mice. Male Tg+
mice developed a slightly accelerated paralysis compared to female
Tg+ mice (Fig. 1B). However, these differences in progression of
disease were not significant and ultimately both male and female
Tg+ mice developed paralysis.
To determine if IL-10 protein levels were upregulated
systemically or localized to the neural tissue micromilieu, plasma
and cerebrospinal fluid (CSF) of male and female Tg+ healthy
mice, Tg+ sick mice, and Tg2 littermates were harvested and
examined by IL-10 ELISA. We found a significant increase of IL-
10 protein levels in the CSF of Tg+ healthy mice compared to
Tg2 littermates(p,0.001), with significantly (p=0.002) increasing
levels that correlated with development of disease (Fig. 2B). Plasma
levels of IL-10 protein were not elevated in Tg+ mice, indicating
that systemic levels of IL-10 do not change and suggesting that
localized IL-10 expression was driving development of disease.
Figure 1. Disease progression in VMD2-IL-10 transgenic mice. A, Tg+ mice (n=9) develop spontaneous hindlimb paralysis, whereas age-
matched Tg2 littermates (n=5) do not develop disease. B, IL-10 overexpression observed in the testes does not significantly exacerbate disease, as
male Tg+ mice (n=5) develop similar progression of disease compared to Tg+ female mice (n=4).
doi:10.1371/journal.pone.0007121.g001
Macrophages and Polyneuropathy
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7121Additionally, we examined local expression of IL-10 protein by
immunohistochemistry in organs directly affected by disease. We
observed increased expression of IL-10 on the sciatic nerve of Tg+
healthy and sick mice (Fig. S1B and C). IL-10 staining was not
observed on Tg2 sciatic nerve sections (Fig. S1A). Spinal cord
expression of IL-10 appeared to be localized to the dorsal roots of
Tg+ sick mice (Fig. S1F), and was not apparent on Tg2 or Tg+
healthy spinal cord tissue sections (Fig. S1D and E).
In order to examine the pathology of disease in VMD2-IL-10
Tg mice, histological examination of various tissues from Tg2,
Tg+ healthy, and Tg+ sick mice was performed. H&E staining of
the sciatic nerve from Tg2 and Tg+ healthy mice was normal
(Fig. 3A and B), however, Tg+ sick early (defined as having a
disease score of ,3) sciatic nerve tissue sections revealed a
dramatic infiltration of mononuclear cells (Fig. 3C). Tg+ sick late
(disease grade $3) mice continued to have a dramatic infiltration
of mononuclear cells (Fig. 3D), and also exhibited a significant loss
of sciatic nerve tissue, as evidenced by a decrease in tissue
diameter. Luxol fast blue staining of sciatic nerve tissue revealed
no loss of myelin in Tg2 and Tg+ healthy mice (Fig. 3E and F).
Conversely, Tg+ sick tissues revealed significant loss of myelin
staining (Fig. 3G and H). This correlation of cell infiltrate with loss
of myelin in the sciatic nerve suggested that disease progression in
Tg+ mice was due to an autoimmune attack of the peripheral
nerves. The central nervous system, including the brain (data not
shown) and the spinal cord itself, seemed resistant to the effects of
increased IL-10, as H&E staining of the spinal cord tissue revealed
no evidence of cell infiltrate in Tg2,T g + healthy, nor Tg+ sick
mice (Fig. 3I-L). The dorsal roots of Tg+ sick mice do reveal a
slight ‘‘moth-eaten’’ appearance, and some loss of myelin staining
was observed in these dorsal roots (Fig. 3O and P). No loss of
myelin was observed in the spinal cords of Tg2 or Tg+ healthy
mice (Fig. 3M and N).
In addition to the sciatic nerve, other peripheral nerves were
examined for cellular infiltrate. In nerves from the brachial plexus,
significant infiltrate was observed in Tg+ sick mice (Fig. S2C), but
not in Tg2 or Tg+ healthy mice (Fig. S2A and B). This is
interesting as no paralysis was observed in the forelimbs during the
course of disease. This suggests that disease in Tg+ mice may be
ascending to the forelimbs, as often seen in human CIDP, yet mice
perish prior to forelimb paralysis occurs. No cellular infiltrate was
observed in the femoral nerve, regardless of disease state (Fig. S2D
and F). In the optic nerve, no cellular infiltration was observed in
Tg+ sick mice (Fig. S2G), despite the increased expression of
VMD2 and IL-10 in the eyes of these animals. A summary of
tissues examined, cellular infiltration, and phenotype is displayed
in Table S1.
To identify the cellular infiltrate observed in the sciatic nerve of
Tg+ sick mice, tissues from Tg2 and Tg+ sick mice were
harvested and flow cytometry was used to identify various immune
cells, including macrophages (F4/80), monocytes (Cd11b), T cells
(CD3), and neutrophils (Gr1). Spleens from Tg+ sick mice revealed
decreased macrophages (p,0.001) and increased T cell popula-
tions (p=0.008) compared to Tg2 littermates (Fig. 4A). The
sciatic nerve of Tg+ sick mice revealed a significant infiltration of
macrophages (p=0.001) and monocytes (p=0.002) compared to
Tg2 mice, but no difference in neutrophils (p=0.469) was
observed (Fig. 4B). These results suggest that there is recruitment
of macrophages from the spleen to these tissues. Although not
evident in H&E staining, spinal cord tissue from Tg+ sick mice had
a significant infiltration of macrophages (p=0.002) as well
(Fig. 4C), which likely corresponds to cellular infiltration into the
dorsal roots and not actual cord tissue.
Additionally, sciatic nerve tissue sections were stained with
APC-conjugated anti-F4/80 antibody and examined by confocal
microscopy. Tg2 and Tg+ healthy mice exhibited no infiltration
of macrophages into the sciatic nerve (Fig. 4D and E). Tg+ sick
early mice exhibited abundant macrophages in the sciatic nerve,
virtually infiltrating the entire tissue (Fig. 4F). Sciatic nerve tissue
from Tg+ sick late mice demonstrated infiltrating macrophages
Figure 2. IL-10 gene and protein expression in VMD2-IL-10 transgenic mice. A, Gene expression of IL-10 is upregulated in the eye, testes,
brain, sciatic nerve, and spinal cord of Tg+ sick animals compared to tissues from Tg2 littermates, as determined by quantitative real-time RT-PCR. B,
IL-10 protein levels from the cerebrospinal fluid (CSF) significantly increase in correlation with disease progression (p#0.002 for each stage of
disease), as determined by IL-10 specific ELISA. Plasma levels of IL-10 are not elevated in Tg+ mice.
doi:10.1371/journal.pone.0007121.g002
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tissues. Again, tissue loss was evident in Tg+ sick late mice. This,
combined with the above observation of macrophages infiltrating
the sciatic nerve at the time of disease suggested that macrophage-
mediated demyelination of the sciatic nerve and subsequent loss of
tissue resulted in clinical disease.
To determine the gene expression cytokine profile of various
disease-affected tissues, spleen, sciatic nerve, and spinal cord tissue
from Tg+ healthy and sick mice were harvested and examined for
various pro- and anti-inflammatory cytokines by quantitative real-
time PCR. Using Tg+ healthy tissues as a baseline comparison,
Tg+ sick early and sick late spleens exhibited very little change in
cytokine gene expression (Fig. 5A). Sciatic nerves, however,
exhibited a primarily pro-inflammatory cytokine profile, with
cytokine expression levels increasing with disease progression
(Fig. 5B). These cytokines include FasL, IFN-c, and IL-12. The
anti-inflammatory marker arginase (Arg1) was also increased in
sciatic nerve tissues from sick mice, suggesting a possible attempt
to squelch this burst of autoimmune activity. Pro- and anti-
inflammatory cytokine gene expression is also evident in spinal
cord tissue of Tg+ sick mice (Fig. 5C), albeit at drastically reduced
levels compared to the sciatic nerve tissue. Pancreas specific IL-10
transgenic mice have been shown to develop spontaneous
inflammation and diabetes [9,10]. Cellular infiltration into the
pancreas correlated with increased expression of adhesion
molecules on pancreatic endothelium, including intercellular
adhesion molecule 1 (ICAM-1) [10]. To determine if VMD2-IL-
10 Tg mice exhibited increased ICAM-1 expression, sciatic nerve
and spinal cord tissues sections were stained with PE-conjugated
anti-ICAM-1 antibody. Tg2 littermates exhibit no expression of
ICAM-1 on sciatic nerve tissue sections (Fig. 6A), whereas Tg+
healthy and sick mice demonstrated significant staining of ICAM-
1 antibody on the surface of the sciatic nerve tissue (Fig. 6B and C).
Increased ICAM-1 expression was not evident on spinal cord
dorsal roots in Tg+ healthy mice (Fig. 6D), but was evident once
Tg+ mice develop disease (Fig. 6E). No increase in ICAM-1
expression was observed in the cerebellum of Tg2,T g + healthy,
or Tg+ sick mice (data not shown), reflecting that sites spared of
cellular infiltration lack ICAM-1 expression.
In our VMD2-IL-10 transgenic mice, it appears that disease
progression correlated with infiltration of macrophages into the
sciatic nerve and subsequent demyelination. However, paralysis
can be initiated by a variety of mechanisms other than antecedent
demyelination. In addition, although mice did not clinically
demonstrate evidence of weakness or paralysis prior to demyelin-
ation, it remained possible there was some subclinical axonal
dysfunction prior to initiation of demyelination. This includes
inherent neuronal defects resulting in neuromuscular dysfunction.
In order to determine if Tg+ mice have underlying axonal
dysfunction prior to development of paralysis, we first stained
Figure 3. Pathology of disease in VMD2-IL-10 transgenic mice: sciatic nerve sections from mice. H&E staining of the sciatic nerve (A–D)
reveals no significant cellular infiltrate in wild-type A, Tg2 littermates or B, Tg+ healthy mice. C, Tg+ mice in the early stages of disease (clinical score
,3) reveal a significant infiltration of cells into the sciatic nerve. D, Tg+ mice in the late stages of disease (clinical score $3) reveal cellular infiltration
and loss of tissue diameter. Luxol fast blue staining of the sciatic nerve E–H, reveal no demyelination in (E) wild-type mice or F, Tg+ healthy animals.
G,H, Significant demyelination is observed in both Tg+ sick early and Tg+ sick late mice. I–L, H&E staining of the spinal cord reveals no significant
infiltration of cells, regardless of stage of disease. M–P, Luxol fast blue staining of the spinal cord reveal no observable demyelination in M, wild-type
and N, Tg+ healthy animals. O, Tg+ sick early and P, late mice both demonstrate significant demyelination of the dorsal roots of spinal cord tissue. All
images acquired at 1006magnification.
doi:10.1371/journal.pone.0007121.g003
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neurofilament phenotype. The SMI-31 antibody reacts with a
phosphorylated epitope in extensively phosphorylated neurofila-
ment H and, to a lesser extent, with neurofilament M, a sign of
normal neurofilament status. SMI 31 reacts broadly with thick and
thin axons and some dendrites such as basket cell dendrites,
but not Purkinje cell dendrites. Nerve cell bodies are generally
unreactive, and other cells and tissues are unreactive except
for peripheral axons. Damage to neurofilaments results in de-
phosphorylation of neurofilaments, and thus less reactivity with
Figure 4. Cellular infiltrate in VMD2-IL-10 transgenic mice. A, Flow cytometry of spleens from animals reveal a slightly decreased presence of
F4/80+ macrophages (p,0.001) and increased CD3+ T cells (p=0.008) in Tg+ sick mice compared to Tg2 littermates. B, Flow cytometry of sciatic
nerve tissue from mice reveal a significant infiltration of F4/80+ (p=0.001) and CD11b+ cells (p=0.002) into the sciatic nerve of Tg+ sick mice
compared to Tg2 mice. C, Flow cytometry of spinal cord tissue reveals an increase in F4/80+ cells (p=0.002) into the spinal cord of Tg+ sick mice.
Sciatic nerve sections (200X) from mice were stained with APC conjugated anti-F4/80 antibody reveal no infiltration of F4/80+ macrophages in D,
wild-type or E, Tg+ healthy animals. Significant infiltration of macrophages is seen in F, Tg+ sick early mice. Decreased macrophages and loss of tissue
are observed in sciatic nerves from G, Tg+ sick late mice.
doi:10.1371/journal.pone.0007121.g004
Figure 5. Inflammatory gene expression profiles of various tissues from VMD2-IL-10 transgenic mice. A, Spleens from Tg+ mice reveal
relatively low expression of pro-inflammatory cytokines, with the exception of increased FasL in Tg+ sick early spleens. B, Sciatic nerve tissues,
however, demonstrate multiple cytokines with increased gene expression, both pro-inflammatory (FasL, IL-12, IFN-g) and anti-inflammatory (Arg1). C,
Spinal cord tissues have few cytokines with increased expression, and only at late stages of disease.
doi:10.1371/journal.pone.0007121.g005
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with SMI-31, reflecting a healthy axonal phenotype (Fig. 7A).
Tg+ mice developed progressively decreased staining with SMI-31
as they developed weakness and paralysis reflecting axonal damage
and loss with onset of paralysis (Fig. 7B and C).
We next examined whether the loss of neurofilament staining
observed in Tg+ mice correlated with a loss of activity at times
preceding macrophage infiltration and hind limb paralysis. This
was done by examining voluntary wheel running (VWR) of Tg+
mice and their Tg2 age-matched littermates. Three month-old
Tg+ mice, prior to developing clinical signs of weakness or motor
dysfunction, showed no significant difference in VWR compared
to Tg2 littermates, as determined by distance, time, and speed on
the wheel (Fig. 7D). This demonstrates that although mice at 3
months of age demonstrate decreased neurofilament staining
(Fig. 7B), loss of function in these animals does not progress until
cellular infiltration and demyelination occurs, indicating that
macrophages are the primary mediators of disease in Tg+ mice.
This also demonstrates that paralysis and/or loss of activity is not
due to an inherent neurological dysfunction in Tg+ mice.
Disease progression in VMD2-IL-10 transgenic mice appears to
develop in two stages. First, overexpression of IL-10 results in
upregulation of ICAM-1 on sciatic nerve tissue. Secondly,
macrophages infiltrate sciatic nerve tissue, cause demyelination,
neuronal dysfunction, and ultimately paralysis. We wanted to test
whether the onset of disease could be delayed or disease severity
ameliorated by attempting to remove important components of
disease progression: IL-10 and macrophages. We first attempted to
block IL-10 protein expression with blocking antibodies to IL-10.
Tg+ mice were treated with intraperitoneal injections of 250 mg
anti-IL-10 antibody or rat IgG control antibody i.p. 1–2x weekly.
Anti-IL-10 immunotherapy did not successfully delay progression
of disease compared to isotype control administration (Fig. S2I).
Higher doses of anti-IL-10 were not successful and resulted in
toxicity (data not shown). The lack of success with i.p.
administration of anti-IL-10 was not surprising, as systemic levels
of IL-10 were not elevated in transgenic mice (Fig. 2B). Moreover,
systemically delivered antibodies would not readily cross blood-
brain barriers and penetrate nerve tissues.
We next attempted to ameliorate disease by depletion of
macrophages with clodronate liposomes. Tg+ mice were treated
with intraperitoneal injections of clodronate or PBS liposomes
(200 ml initial injection; 100 ml each subsequent injection) twice
weekly [11]. Liposome treatment commenced immediately prior
to onset of disease (day 100). Tg+ mice treated with clodronate
liposomes developed paralysis at a significantly reduced tempo
compared to PBS liposome-treated Tg+ mice (Fig. 8A). Clodro-
nate liposome treatment was continued for 2 months, and ceased
at day 162 due to toxicity related to repeated liposome injection.
At time of cessation, the clinical score of paralysis was 1.560.41
for clodronate treated mice compared to 3.7560.96 for PBS-
treated mice. PBS liposome-treated Tg+ mice continued to live
past day 162, suggesting that toxicity is directly attributable to the
clodronate and not to liposomes. Clodronate-liposome treatment
resulted in significantly reduced macrophage infiltrate into the
sciatic nerve (Fig. S2H).
It was previously observed that gene expression of FasL was
upregulated in the spleen and sciatic nerve of Tg+ mice (Fig. 4A
and B). Since membrane bound FasL can regulate cell death
[1,3,12], we hypothesized that this increase in FasL may be due to
increased expression on Tg+ macrophages, and that these
macrophages are utilizing FasL to mediate myelin-producing
Schwann cell death in the sciatic nerve, leading to demyelination
of the sciatic nerve and ultimately paralysis of the animal. To
determine if Tg+ macrophages utilize FasL to induce Schwann cell
death, a modified macrophage/target-cell co-culture experiment
Figure 6. ICAM-1 expression in VMD2-IL-10 transgenic mice. Sciatic nerve sections from A, Tg2 mice demonstrate no ICAM-1 expression, yet
B, Tg+ healthy and C, Tg+ sick sciatic nerve sections reveal significant expression of ICAM-1 on the outer surface of the sciatic nerve. D, Spinal cord
sections from Tg+ healthy mice reveal no expression of ICAM-1, yet the dorsal roots of E, Tg+ sick mice eveal positive staining of ICAM-1.
doi:10.1371/journal.pone.0007121.g006
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and co-cultured with radioactively labeled murine Schwann cells
at an effector:target ratio of 10:1. Schwann cell death was
determined by the release of
3H-thymidine into the cell
supernatant. The co-culture was performed with anti-FasL
blocking antibodies or isotype control antibodies present. Tg+
macrophages induced significant Schwann cell cytotoxicity, and
was due to FasL mediated death, as blocking antibodies to FasL
significantly inhibited Schwann cell death (Fig. 8B). Therefore,
macrophages-mediated cytotoxicity of myelin-producing Schwann
cells through FasL-dependent pathways. To determine if FasL was
indeed causing demyelination and paralysis in vivo, we bred
VMD2-IL-10 Tg+ mice with C57BL/6-Fas
lpr mice, which harbor
a spontaneous mutation in Fas that prevents Fas-FasL interaction
and signaling. We found that Tg+ lpr homozygous mice failed to
develop progressive disease and paralysis compared to Tg+ mice
(Fig. 8C), confirming that Fas expression on neural tissues is
necessary for macrophage- and FasL-mediated demyelination and
paralysis in Tg+ mice.
Discussion
In conclusion, VMD2-driven transgenic expression of IL-10
results in macrophage recruitment and FasL-mediated demyelin-
ation of the sciatic nerve, axonal death, and ultimately paralysis.
Although IL-10 is an immunosuppressive cytokine at normal
levels, overexpression of IL-10 exacerbates inflammation. IL-10
upregulates the adhesion molecules ICAM-1, that causes increased
trafficking of inflammatory macrophages into the sciatic nerve via
CD11b expressed on the macrophage surface, a receptor for the
ligand ICAM-1[14].
Macrophages and sciatic nerve tissue in Tg+ sick mice exhibit a
markedly pro-inflammatory gene expression profile, as evident by
upregulated expression of FasL, IFN-c, and IL-12. This contrasts
with the known effect of IL-10 as an immunosuppressive cytokine
that polarizes macrophages towards an anti-inflammatory and
pro-angiogenic gene expression profile [1,2]. Cytokines observed
at these timepoints provide an overall ‘‘snapshot’’ of the cytokine
milieu of Tg+ sick mice at early and late stages. Also, comparisons
with Tg+ healthy mice rather than Tg2 mice provide a
representation of disease progression in Tg+ mice rather than
comparing Tg+ mice with a wild-type phenotype. Increased
expression of FasL may be the cause of demyelination and tissue
loss, as Tg+ macrophages induced death of myelin-producing
Schwann cells in a FasL-dependent manner, and Tg+ lpr
homozygous mice failed to develop progressive disease.
It has been considered that IL-10 may be a potential therapeutic
in the treatment of autoimmune diseases [15]. Administration of
recombinant IL-10 (rIL-10) reduces disease severity in experi-
mental models of diabetes, rheumatoid arthritis, and inflammatory
bowel disease [16,17,18]. However, the outcome of rIL-10 therapy
in autoimmune diseases of the nervous system is unclear. In
models of experimental autoimmune encephalomyelitis (EAE),
intravenous injection of rIL-10 exacerbated disease [19], while
Figure 7. Neural phenotype of VMD2-IL-10 transgenic mice. A, Tg2 sciatic nerve sections are strongly reactive with the SMI-31 antibody,
indicating normal neurofilament phosphorylation and phenotype. B, Sciatic nerve sections from 3 month-old Tg+ mice demonstrate decreased
reactivity with SMI-31, indicating a decreased loss of neurofilament in the early stages of disease prior to observable levels of cellular infiltration. C,
Tg+ sick sciatic nerve sections, however, demonstrate even less reactivity with SMI-31, indicating dephosphorylation of neurofilaments and neural
loss correlating with cellular infiltration. D, Voluntary wheel running (VWR) experiments with Tg+ mice (n=3) before cellular infiltration and disease
onset (3-months old) reveals no loss of motor function (distance p=0.320; time p=0.341; speed p=0.576) prior to macrophage infiltration compared
to age-matched Tg2 littermates (n=3).
doi:10.1371/journal.pone.0007121.g007
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[20]. Targeting delivery of IL-10 to the central nervous system
does not increase the success of IL-10 treatment, as intracranial
injection of soluble rIL-10 or plasmids encoding IL-10 did not
suppress EAE [21]. Therefore, administration and/or localization
of IL-10 may be critical in determining its immunoregulatory
function in autoimmune diseases of the nervous system.
In our VMD2-IL-10 transgenic animals, IL-10 is not only
upregulated in the sciatic nerve, but also the eye, brain, spinal
cord, and especially the testes. However, our disease phenotype is
restricted primarily to the sciatic nerve, and to a much lesser extent
the caudal spinal cord. One hypothesis for why other organs are
spared immune mediated destruction may be the immune
privileged environment that these tissues possess. The eye, brain,
and spinal cord are well known immune privileged sites, and
possess various anti-inflammatory and pro-apoptotic molecules
that may dampen an immune response in these tissues [22,23].
Also, as the disease progresses from early stages to late stages,
cellular infiltration and/or demyelination may be ascending from
lower limbs to upper extremities, similar to human CIDP. This
may explain while caudal spinal cord and brachial plexus nerves
are not affected until later stages of disease. However, the effect of
cellular infiltration into these tissues at these later stages on disease
phenotype is not fully understood.
Polyneuropathies are a common neurological disease that
affects the peripheral nervous system in humans. The use of
animal models has helped to recapitulate and understand human
neuropathies, however the transfer of treatment modalities from
preclinical to clinical settings has been highly unsuccessful [24].
This may be due to the fact that established animal models do not
precisely mimic human disease. For example, experimental
autoimmune neuritis (EAN), the most widely used model of
Guillain-Barre ´ syndrome (GBS), involves the immunization of rats
with peripheral myelin homogenates, myelin proteins, or derived
peptides to produce disease [24]. This results in a primarily T cell
mediated attack and demyelination of the peripheral nerves. GBS,
however, results from macrophages serving as the primary effector
cells in the demyelination of the peripheral nervous system. The
Figure 8. Macrophage mediated disease and Fas ligand-mediated cytotoxicity of myelin-producing Schwann cells in VMD2-IL-10
transgenic mice. A, Depletion of macrophages in Tg+ mice by administration of clodronate liposomes i.p. twice weekly (n=6) results in significant
delayed onset of disease compared to PBS liposome-treated Tg+ mice (n=5). B, Tg+ macrophages and Schwann cells were co-cultured in the
presence of anti-FasL antibodies or isotype control. Cytotoxicity of Schwann cells is observed with macrophages + IgG, yet cytotoxicity is significantly
decreased when FasL is blocked *(p=0.0035). Antibodies alone do not induce Schwann cell cytotoxicity. C. VMD2-IL-10 Tg+ mice were bred with
C57BL/6-Fas
lpr mice, which harbor a spontaneous mutation in Fas that prevents Fas-FasL interaction and signaling. Tg+ lpr homozygous mice failed
to develop progressive disease and paralysis compared to Tg+ mice.
doi:10.1371/journal.pone.0007121.g008
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model for the study of GBS pathogenesis and treatment. Animal
models of CIDP have been extremely problematic in mimicking
human disease. EAN models are acute, with disease recovery
occurring substantially by 28 days. Other animal models for CIDP
involve repeated myelin immunization that may be combined with
immunosuppression [24]. These models are not ideal, as they are
primarily performed in species other than mice, hampering the use
of genetic knockout animals.
Interestingly, a mouse model of CIDP has been previously
demonstrated in B7-2 deficient non-obese diabetic (NOD) mice
[25]. This animal model results in the infiltration of T cells and
dendritic cells into the peripheral nervous system. However, disease
progression was not congruent between both sexes, and cellular
infiltration lacked macrophages as observed in human CIDP. In
addition, autoimmune disease in these mice was manifested on two
genetic backgrounds with preexisting immunodeficiencies. VMD2-
IL-10 transgenic mice may be an ideal mouse model for the study of
the pathobiology of CIDP and may be an excellent surrogate to
investigate therapeutic options in this disease.
Materials and Methods
Ethics Statement
All work was carried out in accordance with Association for
Research in Vision and Ophthalmology (ARVO) guidelines.
Comprehensive protocols of animal care and experimental design
outlined in this study are on file and have been approved by the
Washington University Committee on the Humane Care of
Laboratory Animals (CHCLA). All animal caretakers and
laboratory personnel have appropriate approvals based on specific
AALAC-approved training programs. The facilities are inspected
at regular intervals by a local University Committee and by
unannounced visits directed by the Federal Government.
Mice
VMD2-IL-10 transgenic (Tg) mice were constructed to overex-
press IL-10 (pVMD2-placF was provided by Noriko Ezumi, Johns
Hopkins Medical School). The human VMD2 promoter was
removed and cloned into the pCI plasmid (Promega), replacing
the CMV promoter, and then placed the IL-10 ORF downstream
[3]. Tg mice were produced by injecting fertilized mouse oocytes
with transgene DNA by standard protocols in the Washington
University Department of Ophthalmology and Visual Science
Molecular Biology Core facility. B6CBAF2 founders were screened
by PCR and used for backcrossing to C57BL/6 mice. IL-10
expression was verified by RT-PCR (forward – 59 GGA CTT TAA
GGG TTA CTT GGG TTG CC 39; reverse – 59 CAT TTT GAT
CAT CAT GTA TGC TTC T 39). Transgene-negative littermates
were used as wild-type control mice.
C57BL/6-Fas
lpr mice were purchased from Jackson Laborato-
ries (Bar Harbor, ME) and bred with VMD2-IL-10 Tg+ mice. The
resulting F1 offspring were screened for lpr (according to Jackson
Laboratory instructions) and Tg+ (as described above) status, and
Tg+ lpr heterozygous mice were bred. F2 generation Tg+ lpr
homozygous offspring were identified by PCR and monitored for
disease progression.
Clinical score of paralysis
Disease severity was scored as: grade 0, normal; grade 1, partial
paralysis of 1 hind limb; grade 2, complete paralysis of 1 hind
limb; grade 3, partial paralysis of both hind limbs; grade 4,
complete paralysis of both hind limbs; grade 5, moribund or death.
Data is reported as mean6SEM.
Immunohistochemistry
5-mm paraffin embedded sections were stained with Hematox-
ylin and Eosin (H&E), Luxol fast blue myelin specific stain,
allophycocyanin (APC)-conjugated anti-mouse F4/80 (BM8;
eBioscience), phycoerythrin (PE)-conjugated anti-mouse CD54
(anti-ICAM-1; N1/1.7.4; eBioscience), PE-conjugated Rat anti-
mouse IL-10 (BD Biosciences), or mouse anti-phosphorylated
neurofilament antibody (SMI-31; Covance) followed by fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG1 (Caltag).
All antibodies were used at 1 mg/ml. Staining was examined by
confocal microscopy (Zeiss LSM 510).
Flow cytometry
Single-cell suspensions from spleens, sciatic nerves, and spinal
cords from wild-type and transgene-positive sick mice were
obtained and stained with PE-conjugated IgG2a (eBM2a;
eBioscience), PE-conjugated anti-mouse F4/80 (BM8;
eBioscience), FITC-conjugated anti-mouse CD3e (1 45-2C11;
eBioscience), or FITC-conjugated anti-mouse Cd11b (M1/70; BD
Biosciences). Cells were then assessed for fluorescence in a
FACScan flow cytometer (BD Biosciences) and the results were
analyzed using Cellquest software (BD Biosciences).
Enzyme-linked immnosorbent assay (ELISA)
Cerebrospinal fluid (CSF) was collected from the cisterna
magna[26], and plasma was sampled via cardiac bleed from wild-
type, transgenic healthy, and transgenic sick mice. CSF and
plasma samples were then assayed for IL-10 protein levels via
mouse IL-10 Quantikine ELISA kit (R&D Systems). CSF and
plasma from 3 separate animals for each group were assayed.
Quantitative Analysis of Gene Expression (Quantitative
Real-Time RT-PCR)
Relative expression of various inflammatory proteins were
performed as previously described[1]. Tissues examined were
whole spleens, sciatic nerve tissue, and spinal cord tissue from
VMD2-IL-10 Tg + healthy, early sick (grade ,3), and late sick
(grade $3) mice.
Taqman Gene Expression Assay Mixes used (primer/probe sets)
include b-actin (Mm00607939_s1); TNF-a (Mm00443258_m1); IL-6
(Mm00446190_m1); IL-12 (Mm01288989_m1); FasL (Mm00438864_
m1); IL-1b (Mm00434228_m1); IFN-c (Mm00801778_m1); and Arg1
(Mm00475988_m1). Tissues from transgene-positive healthy mice
were used as a baseline comparison
Voluntary Wheel-Running (VWR)
Mice were tested after being segregated to individual cages with
a voluntary exercise wheel recorded by an automatic speedometer.
After a 5-day acclimation period, two 24 h running periods were
recorded for speed, total distance, and total time on the wheel.
In vivo anti-IL-10 antibody treatment
VMD2-IL-10 Tg + mice were treated with intraperitoneal
injections of rat anti-mouse IL-10 blocking antibody (250 mg;
JES5.2A5; Genzyme) or Rat IgG (250 mg; Equitech-Bio).
Injections were administered 1–2 times weekly beginning on day
50. Paralysis was monitored upon day of injection.
Liposome-encapsulated dichloromethylene
diphosphonate
Multilamellar liposomes were prepared as described previously
[27]. The cytotoxicity of C12MDP-LIP and PBS-LIP were tested
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Liposomes were stored at 4uC for up to 1 month.
In vitro macrophage-mediated cytotoxicity assay
Utilizing a modified version of a macrophage/target cell
cytotoxicity assay from previously published reports [13], the
murine Schwann cell line, SW10 (ATCC), was grown at the
proliferative temperature of 33uC. SW10 cells were trypsinized,
washed, and resuspended in DMEM media with 8 mCi
3H-
thymidine add per 10 ml media. Cells were then plated in 96-well
round-bottom plates at 1610
4 cells/well at 37uC and allowed to
adhere for 24 hours. This temperature prevents Schwann cell
proliferation but induces myelin production [28]. Splenic
macrophages from Tg+ sick mice were isolated by magnetic
separation as described above. Schwann cells were washed and
macrophages were added and allowed to co-culture for 24 hours.
After incubation, cells were lightly centrifuged and 100 mlo f
supernatant was removed and placed in 2 ml scintillation fluid.
Spontaneous release was determined by Schwann cells incubated
with no macrophages, and maximum release was determined by
lysis of cells with Qiagen lysis buffer RLT. Specific release was
determined by the equation:
Specific release ~ experimental release-spontaneous release ðÞ = ½
maximum release-spontaneous release ðÞ   |100:
Co-cultures of macrophages and Schwann cells were performed
in the presence of blocking antibodies to FasL or Hamster IgG
(10 mg/ml; eBioscience). Also, Schwann cells alone were incubated
with antibodies to ensure no antibody-mediated cytotoxicity.
Cytotoxicity data from quintuplicate cultures are presented as
the mean6SD.
Statistics
A student’s t test was performed for statistical analysis. A p value
of ,0.05 was considered significant.
Supporting Information
Figure S1 IL-10 gene and protein expression in VMD2-IL-10
transgenic mice. A, Tg- and B–C, Tg+ mice reveal increased IL-
10 expression on the outer surface of the sciatic nerve. Spinal cord
sections (200X) from D, Tg- and E-F, Tg+ reveal increased IL-10
on the dorsal roots of Tg+ mice only after development of disease.
Found at: doi:10.1371/journal.pone.0007121.s001 (0.45 MB TIF)
Figure S2 Additional peripheral nerve sections and anti-IL-10
treatment. No immune cell infiltration is observed in the A,
brachial plexus of Tg 2 or B, Tg+ healthy mice. Cellular
infiltration is observed in Tg+ sick mice C, despite the lack of
disease phenotype in the forelimbs. Immune cell infiltrate is not
observed in the femoral nerves of D, Tg2,E ,T g + healthy, and F,
Tg+ sick mice. G, Optic nerve sections from Tg+ sick late mice do
not reveal infiltration of immune cells despite increased VMD2
and IL-10 expression. H, Sciatic nerve sections from clodronate-
liposome treated Tg+ mice at day 162 reveal cellular infiltrate, yet
at significantly decreased levels. I, Anti-IL-10 immunotherapy
(250 mg i.p. twice weekly) of Tg+ mice (n=4) does not decrease
disease onset compared to isotype control treated Tg+ mice (n=3).
Found at: doi:10.1371/journal.pone.0007121.s002 (0.73 MB TIF)
Table S1 Summary of cellular infiltration and disease phenotype
in various nervous tissues from VMD2-IL-10 Tg2 and Tg+ mice.
Found at: doi:10.1371/journal.pone.0007121.s003 (0.04 MB
DOC)
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